[XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure]. We report the case of a patient with a postoperative recurrence of colon cancer who received XELOX plus bevacizumab chemotherapy whilst undergoing hemodialysis.  XELOX plus bevacizumab chemotherapy was administered. 
XELOX
[XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure]. We report the case of a patient with a postoperative recurrence of colon cancer who received XELOX plus bevacizumab chemotherapy whilst undergoing hemodialysis.  XELOX plus bevacizumab chemotherapy was administered. 
Bevacizumab
[XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure]. We report the case of a patient with a postoperative recurrence of colon cancer who received XELOX plus bevacizumab chemotherapy whilst undergoing hemodialysis.  A 73-year-old man had been receiving maintenance hemodialysis for 9 years due to chronic renal failure.  Chemotherapy with molecular target drugs is currently recommended for advanced/metastatic colorectal cancer; however, a standardized strategy for hemodialysis patients is not established.  As the number of hemodialysis patients receiving chemotherapy for some cancers is likely to increase in the future, it will be necessary to consider chemotherapy strategies for hemodialysis patients.
Hemodialysis